Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study-Reference-Cited by-同舟云学术

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Barlesi Fabrice¹,Dixmier Adrien²,Debieuvre Didier³,Raspaud Christophe⁴,Auliac Jean-Bernard⁵,Benoit Nicolas⁶,Bombaron Pierre⁷,Moro-Sibilot Denis⁸,Audigier-Valette Clarisse⁹,Asselain Bernard¹⁰,Egenod Thomas¹¹,Rabeau Audrey¹²,Fayette Jérôme¹³,Sanchez Myriam Locatelli¹⁴,Labourey Jean-Luc¹⁵,Westeel Virginie¹⁶,Lamoureux Pauline¹⁷,Cotte François-Emery¹⁷,Allan Victoria¹⁸,Daumont Melinda¹⁹,Dumanoir Juliette¹⁷,Reynaud Dorothée¹⁷,Calvet Christophe Yannick¹⁷,Ozan Nicolas¹⁷,Pérol Maurice²⁰

Affiliation:

1. CNRS, INSERM, CRCM, Assistance Publique Hôpitaux de Marseille, Hopital Nord, Pavillon Mistral, 6ème Étage A, Chemin des Bourrely, Aix Marseille University, Marseille, France

2. Department of Pulmonology, Centre Hospitalier Régional d’Orléans, Orléans, France

3. Respiratory Medicine Department, Groupe Hospitalier De La Région Mulhouse Sud-Alsace, Hopital Emile Muller, Mulhouse, France

4. Department of Pulmonology, Clinique Pasteur, Toulouse, France

5. Department of Pulmonology, Centre Hospitalier Intercommunal de Créteil, Créteil, France

6. Department of Pulmonology, Clinique de l’Europe, Amiens, France

7. Department of Pulmonology, Hôpital Privé Jean Mermoz, Lyon, France

8. Thoracic Oncology Unit, SHUPP, Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble Cedex, France

9. Department of Pulmonology, Hôpital Sainte-Musse, Toulon, France

10. Department of Biostatistics, Institut Curie, Paris, France

11. Department of Cutaneous and Thoracic Oncology, Centre Hospitalier Universitaire Dupuytren, Limoges, France

12. Thoracic Oncology Department, Centre Hospitalier Universitaire de Toulouse, Hopital Rangueil, Toulouse, France

13. Department of Medicine, Centre Léon Bérard, Lyon, France

14. Department of Thoracic Oncology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France

15. Department of Oncology, Hôpital de Carcassonne, Carcasonne, France

16. Chest Disease Department, University Hospital, INSERM UMR 1098, University of Bourgogne Franche-Comté, Besançon, France

17. Bristol-Myers Squibb, Rueil-Malmaison, France

18. Bristol-Myers Squibb, Uxbridge, UK

19. Bristol-Myers Squibb, Braine-l’alleud, Belgium

20. Department of Medical Oncology, Centre Léon Bérard, Lyon, France

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1744898

Reference34 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

2. National Cancer Institute. The essential facts and figures of cancer in France. 2019 [accessed 2019 Feb 26]. http://www.e-cancer.fr/Actualites-et-evenements/Actualites/L-Institut-publie-L-essentiel-des-faits-et-chiffres-des-cancers-en-France-edition-2019.

3. Cancer statistics, 2019

4. Epidemiology, risk factors, symptomatology, TNM classification of Non Small Cell Lung Cancer. An overview while waiting the 8th TNM classification

5. Couraud S, Westeel V, Ranchon F, Toffart A-C, Souquet P-J, Editorial board of the 2019 edition. Non-small cell lung cancer. Auvergne Rhône-Alpes guidelines in thoracic oncology. 2019 update 2019 [accessed 2019 May 29]. https://ressources-aura.fr/wp-content/uploads/2018/12/CBNPC_2019_VDEF.pdf.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study;Clinical and Translational Oncology;2024-06-27

2. Transportability of patient outcomes from a US clinical trial to real-world populations - a case study using Lung-MAP S1400I (NCT02785952);2024-05-27

3. Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study;Journal of Endocrinological Investigation;2024-04-29

4. The relationship between immune-related adverse events during ipilimumab monotherapy and survival outcomes among melanoma patients: A systematic review;Journal of Oncology Pharmacy Practice;2024-04-05

5. Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis;Respiratory Medicine and Research;2023-11